ArticleFrontiers in pharmacology2022
Data mining and safety analysis of BTK inhibitors: A pharmacovigilance investigation based on the FAERS database.
Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- Cardiac safety profiles of first-generation vs second-generation BTK inhibitors: a meta-analysis.The oncologist · 2026Pooled it
- Comparative atrial fibrillation risk across Bruton's tyrosine kinase inhibitors in B-cell malignancies: A nationwide population-based study.British journal of haematology · 2026Article
- Generational safety profiles of BTK inhibitors: adverse reaction signals and real-world evidence from the FAERS database.Frontiers in medicine · 2026Article
- Ibrutinib for therapy of steroid-refractory chronic graft-versus-host disease: a multicenter real-world analysis.Blood advances · 2025Article
- Real-world safety profile of elexacaftor/tezacaftor/ivacaftor: a disproportionality analysis using the U.S. FDA adverse event reporting system.Frontiers in pharmacology · 2025Article
- Real-world safety profile of zanubrutinib: a disproportionality analysis based on the FAERS database.BMJ open · 2024Article
- Ibrutinib and venetoclax in combination for chronic lymphocytic leukemia: synergy in practice.Blood neoplasia · 2024Article
- Data mining and analysis of adverse event signals associated with teprotumumab using the Food and Drug Administration adverse event reporting system database.International journal of clinical pharmacy · 2024Article
- Signal detection of adverse events associated with gabapentinoid use for chronic pain.Pharmacoepidemiology and drug safety · 2024Article
- A disproportionality analysis for assessing the safety of FLT3 inhibitors using the FDA Adverse Event Reporting System (FAERS).Therapeutic advances in drug safety · 2024Article
- A real-world pharmacovigilance analysis of adverse events associated with irbesartan using the FAERS and JADER databases.Frontiers in pharmacology · 2024Article
- Prognostic risk factors of pneumonia associated with COVID-19 in patients with lymphoma.Frontiers in oncology · 2024Article
- Cardiovascular Toxicities of Ibrutinib: A Pharmacovigilance Study Based on the United States Food and Drug Administration Adverse Event Reporting System Database.Pharmaceuticals (Basel, Switzerland) · 2023Article
- A bibliometric analysis of research progress on pharmacovigilance and cancer from 2002 to 2021.Frontiers in oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.